Atreca, Inc. - (BCEL): Price and Financial Metrics


Atreca, Inc. - (BCEL)

Today's Latest Price: $14.36 USD

0.24 (1.70%)

Updated Oct 27 7:58pm

Add BCEL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

BCEL Stock Price Chart Interactive Chart >

Price chart for BCEL

BCEL Price/Volume Stats

Current price $14.36 52-week high $29.35
Prev. close $14.12 52-week low $9.51
Day low $14.00 Volume 82,100
Day high $14.57 Avg. volume 241,897
50-day MA $14.11 Dividend yield N/A
200-day MA $16.78 Market Cap 517.38M

Atreca, Inc. - (BCEL) Company Bio


Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.


BCEL Latest News Stream


Event/Time News Detail
Loading, please wait...

BCEL Latest Social Stream


Loading social stream, please wait...

View Full BCEL Social Stream

Latest BCEL News From Around the Web

Below are the latest news stories about Atreca Inc that investors may wish to consider to help them evaluate BCEL as an investment opportunity.

Atreca (BCEL) Investor Presentation - Slideshow

The following slide deck was published by Atreca, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 18, 2020

Atreca Reports Second Quarter 2020 Financial Results and Recent Corporate Developments

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on…

GlobeNewswire | August 12, 2020

Atreca to Present at Two Upcoming Virtual Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on…

GlobeNewswire | August 5, 2020

Atreca prices equity offering at $16

Atreca (BCEL) has priced public offering of 7,031,250 shares of its Class A Common Stock and 781,250 Class B Common Shares, each at a price of $16.00/share, for expected gross proceeds of $125M.Underwriters' over-allotment is an additional 1,171,875 Class A Shares.Closing date is July 20.Previously: Atreca announces proposed underwritten public...

Seeking Alpha | July 16, 2020

Atreca, Inc. Announces Pricing of Underwritten Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 16, 2020 -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel.

Yahoo | July 16, 2020

Read More 'BCEL' Stories Here

BCEL Price Returns

1-mo 5.43%
3-mo 8.87%
6-mo -16.17%
1-year 40.78%
3-year N/A
5-year N/A
YTD -7.18%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.7782 seconds.